Page last updated: 2024-12-10

4-hydroxy-3-methoxymethamphetamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxy-3-methoxymethamphetamine: structure given in first source; urinary metabolite of 3,4-(methylenedioxy)methamphetamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081137
SCHEMBL ID3900627
MeSH IDM0213152

Synonyms (13)

Synonym
unii-rby3j6h4jw
4-hydroxy-3-methoxymethamphetamine
117652-28-5
4,3-hmm
2-methoxy-4-(2-(methylamino)propyl)phenol
rby3j6h4jw ,
3-methoxy-4-hydroxymethamphetamine
phenol, 2-methoxy-4-(2-(methylamino)propyl)-
2-methoxy-4-[2-(methylamino)propyl]phenol
SCHEMBL3900627
UVDWYWYWOMOEFX-UHFFFAOYSA-N
DTXSID70922503
Q15634060

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" At each dose, pharmacokinetic parameters for MDMA and its metabolites 3,4-dihydroxymethamphetamine (HHMA), 4-hydroxy-3-methoxymethamphetamine (HMMA), and 3,4-methylenedioxyamphetamine were determined."( Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses.
Maurer, HH; McCann, UD; Mueller, M; Peters, FT; Ricaurte, GA, 2008
)
0.56
" MDMA, and the associated pharmacodynamic consequences."( Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat.
Baumann, MH; Concheiro, M; Huestis, MA; Marrone, GF; Rothman, RB; Scheidweiler, KB, 2014
)
0.4
"Generally, pharmacokinetic studies on 3,4-methylenedioxymethamphetamine (MDMA) in blood have been performed after conjugate cleavage, without taking into account that phase II metabolites represent distinct chemical entities with their own effects and stereoselective pharmacokinetics."( Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans.
Kraemer, T; Liechti, ME; Rickli, A; Schmid, Y; Schmidhauser, C; Steuer, AE, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
"3,4-Methylenedioxymethamphetamine (MDMA) is a racemic drug of abuse and its R- and S-enantiomers are known to differ in their dose-response curve."( Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine.
Huestis, MA; Maurer, HH; Meyer, MR; Schwaninger, AE, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (11.76)18.2507
2000's21 (61.76)29.6817
2010's9 (26.47)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.68 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (13.89%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.78%)4.05%
Observational0 (0.00%)0.25%
Other30 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]